Search fresh public links, source activity, and ready-to-use post angles for Alny.
Fresh curated links around ALNY are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Wall Street expects an even bigger rebound for this beaten-down biotech stock.
At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.
The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi treatments that get into tissues outside the liver.
NEW YORK, Sept. 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Alarum Technologies Ltd. (NASDAQ: ALAR) between...
Roche gains global rights to a Rona Therapeutics RNA interference drug designed to target ALK7, a genetically validated target for obesity and other metabolic indications. The grow...
Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA...
Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on...
NEW YORK, Oct. 5, 2026 /PRNewswire/ --
Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.
ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.
ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran is in Phase 3 testing for the rare...
In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein implicated in the disease.
The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.